Document is current
Any future updates will be listed below
-
Authors
Chetcuti, Lacey https://orcid.org/0000-0002-9360-0851
Hardan, Antonio Y.
Frazier, Thomas W. https://orcid.org/0000-0002-6951-2667
Loth, Eva https://orcid.org/0000-0001-9458-9167
McPartland, James C. https://orcid.org/0000-0002-2570-0746
Youngstrom, Eric A.
Uljarevic, Mirko
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (1R01MH129833, 1R01MH129833, 1R01MH129833, 1R01MH129833)
- License Information
-
More Information
Article History
Received: 19 July 2024
Revised: 24 July 2025
Accepted: 19 August 2025
First Online: 26 August 2025
Competing interests
: This project was supported by grant 1R01MH129833 (Hardan & Uljarevic) by the National Institute of Mental Health. Dr. Hardan has received grant or research support from the National Institutes of Health, Autism Speaks, and the Simons Foundation Autism Research Initiative. He has served on the advisory board/Data and Safety Monitoring Board of Roche. He has co-authored the Stanford Social Dimensions Scale (SSDS). He has served as a consultant to BioBridge, Roche, Finch Therapeutics, and the PTEN Research Foundation and has equity options in iSCAN-R and AI-Measures. He has served on the editorial boards of the Journal of Autism and Developmental Disorders and Child Psychiatry and Human Development. He has held patents (in preparation, filed, or granted) on N-acetyl cysteine, pregnenolone, and arginine vasopressin. Dr. Frazier has received funding or research support from, acted as a consultant to, received travel support from, and/or received a speaker’s honorarium from the PTEN Research Foundation, SYNGAP Research Fund, Malan Syndrome Foundation, ADNP Kids Research Foundation, Quadrant Biosciences, Autism Speaks, Impel NeuroPharma, F. Hoffmann-La Roche AG Pharmaceuticals, the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol-Myers Squibb, Roche Pharma, MaraBio, Scioto Biosciences, National Institutes of Health, and the Brain and Behavior Research Foundation, has equity options in Quadrant Biosciences/Autism Analytica, MaraBio, and Springtide, and has an investor stake in Autism EYES LLC. Dr. McPartland consults with Customer Value Partners, Bridgebio, Determined Health, Apple, Neumarker, and BlackThorn Therapeutics, has received research funding from Janssen Research and Development, serves on the Scientific Advisory Boards of Pastorus and Modern Clinics, and receives royalties from Guilford Press, Lambert, Oxford, and Springer. His effort was supported by NIMH U19 MH108206. Dr. Youngstrom is the co-founder and Executive Director of Helping Give Away Psychological Science, a 501c3; he has consulted about psychological assessment with Signant Health and received royalties from the American Psychological Association and Guilford Press, and he holds equity in Joe Startup Technologies. Dr. Uljarević has received grant or research support from the National Institute of Mental Health, Simons Foundation, Autism Speaks and PTEN Research. He serves on the editorial boards of the Journal of Autism and Developmental Disorders, PLOS One, Frontiers in Psychiatry, and Frontiers in Neuroscience, and has co-authored the Stanford Social Dimensions Scale (SSDS). Drs. Chetcuti and Loth have no financial interests or potential conflicts of interests to declare.
